within Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G02C_OtherGynecologicals.G02CC02_Naproxen;

model Naproxen
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.95,
    Cl = 1.1333333333333332e-07,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.013,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.018333333333333333,
    Tlag = 10.200000000000001);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Naproxen</td></tr><tr><td>ATC code:</td><td>G02CC02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>13</td><td>L</td></tr>
    <tr><td>clearance:</td><td>6.8</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) commonly used for the treatment of pain, inflammation, and fever. It is widely used to manage symptoms associated with arthritis, musculoskeletal disorders, and menstrual pain. Naproxen is an approved and currently marketed medication available over the counter and by prescription.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Välitalo, P, et al., &amp; Kokki, H (2012). Plasma and cerebrospinal fluid pharmacokinetics of naproxen in children. <i>Journal of clinical pharmacology</i> 52(10) 1516–1526. DOI:<a href=\"https://doi.org/10.1177/0091270011418658\">10.1177/0091270011418658</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22067196/\">https://pubmed.ncbi.nlm.nih.gov/22067196</a></p></li><li><p>Mendell, J, et al., &amp; Samama, MM (2013). The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor. <i>Journal of cardiovascular pharmacology</i> 62(2) 212–221. DOI:<a href=\"https://doi.org/10.1097/FJC.0b013e3182970991\">10.1097/FJC.0b013e3182970991</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23615159/\">https://pubmed.ncbi.nlm.nih.gov/23615159</a></p></li><li><p>Kubitza, D, et al., &amp; Zuehlsdorf, M (2007). Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen. <i>British journal of clinical pharmacology</i> 63(4) 469–476. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.2006.02776.x\">10.1111/j.1365-2125.2006.02776.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17100983/\">https://pubmed.ncbi.nlm.nih.gov/17100983</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.G.G02CC02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Naproxen;
